Suppr超能文献

肝细胞癌与肝移植后乙型肝炎病毒复发风险增加相关。

Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.

作者信息

Faria Luciana C, Gigou Michelle, Roque-Afonso Anne M, Sebagh Mylene, Roche Bruno, Fallot Guillaume, Ferrari Teresa C A, Guettier Catherine, Dussaix Elisabeth, Castaing Denis, Brechot Christian, Samuel Didier

机构信息

INSERM, U 785, Villejuif, France.

出版信息

Gastroenterology. 2008 Jun;134(7):1890-9; quiz 2155. doi: 10.1053/j.gastro.2008.02.064. Epub 2008 Mar 4.

Abstract

BACKGROUND & AIMS: Hepatitis B virus (HBV) recurrence after orthotopic liver transplantation (OLT) is significantly reduced by prophylaxis with hyperimmune antibody to hepatitis B surface antigen (anti-HBs) globulins (HBIG) and antiviral drugs. The role of hepatocellular carcinoma (HCC) in HBV recurrence remains unclear. We investigated the association between HCC pre-OLT and HBV recurrence post-OLT.

METHODS

We studied 99 hepatitis B surface antigen-positive patients who underwent OLT for cirrhosis. The median follow-up period was 43 months. All patients received HBIG, and 51 also received lamivudine and/or adefovir. Of these 99 patients, 31 had HCC before OLT. Total HBV DNA and covalently closed circular (ccc)-DNA were measured in tumor and nontumor tissues from the explanted livers of 16 of these 31 HCC patients and, also, in a context of tumor recurrence, in 3 patients who developed HBV/HCC recurrence.

RESULTS

Fourteen patients (14.1%) developed HBV recurrence within a median period of 15 months post-OLT. HCC at OLT, a pre-OLT HBV DNA viral load > or = 100,000 copies/mL, and HBIG monoprophylaxis were independently associated with HBV recurrence post-OLT. Eleven out of the 31 patients with HCC at OLT presented with HBV recurrence and 3 out of the 68 patients without HCC had HBV recurrence (P < .0001). HBV recurrence was more frequent in patients who developed HCC recurrence (7/8 patients, 87.5%) than in those who did not (4/23 patients, 17.4%) (P < .0001). In the 16 explanted livers, cccDNA was detectable in HCC cells in 11 and in nontumor cells in 12. cccDNA was detected in a context of HCC recurrence in 2 of the 3 patients tested who developed HBV/HCC recurrence.

CONCLUSIONS

The associations of HCC pre-OLT, and HCC recurrence with HBV recurrence post-OLT, and the detection of HBV DNA and cccDNA in HCC suggest that HBV replication in tumor cells may contribute to HBV recurrence post-OLT.

摘要

背景与目的

原位肝移植(OLT)后,通过使用乙肝表面抗原(抗-HBs)球蛋白(HBIG)超免疫抗体和抗病毒药物进行预防,乙肝病毒(HBV)复发率显著降低。肝细胞癌(HCC)在HBV复发中的作用仍不明确。我们研究了OLT前HCC与OLT后HBV复发之间的关联。

方法

我们研究了99例因肝硬化接受OLT的乙肝表面抗原阳性患者。中位随访期为43个月。所有患者均接受HBIG治疗,51例还接受了拉米夫定和/或阿德福韦治疗。在这99例患者中,31例在OLT前患有HCC。对这31例HCC患者中的16例患者肝移植切除肝脏的肿瘤组织和非肿瘤组织进行了总HBV DNA和共价闭合环状(ccc)-DNA检测,并且在肿瘤复发的情况下,对3例发生HBV/HCC复发的患者也进行了检测。

结果

14例患者(14.1%)在OLT后中位15个月内发生HBV复发。OLT时存在HCC、OLT前HBV DNA病毒载量≥100,000拷贝/mL以及单纯HBIG预防与OLT后HBV复发独立相关。31例OLT时患有HCC的患者中有11例出现HBV复发,68例无HCC的患者中有3例出现HBV复发(P<0.0001)。发生HCC复发的患者中HBV复发更常见(8例中的7例,87.5%),而未发生HCC复发的患者中则较少见(23例中的4例,17.4%)(P<0.0001)。在16例移植肝脏中,11例HCC细胞中可检测到cccDNA,12例非肿瘤细胞中可检测到cccDNA。在3例发生HBV/HCC复发且接受检测的患者中,2例在HCC复发时检测到cccDNA。

结论

OLT前HCC以及HCC复发与OLT后HBV复发之间的关联,以及在HCC中检测到HBV DNA和cccDNA表明,肿瘤细胞中的HBV复制可能导致OLT后HBV复发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验